Zita Tablet contains Teneligliptin 20 mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, Teneligliptin enhances the levels of incretin hormones, which increase insulin secretion in a glucose-dependent manner and decrease glucagon release, thereby improving glycemic control. Zita Tablet is prescribed as monotherapy or as an adjunct to diet and exercise, and may be used in combination with other antidiabetic agents when glycemic targets are not achieved. It is particularly beneficial in patients with inadequate glycemic control due to its low risk of hypoglycemia and weight neutrality. The recommended dose is 20 mg once daily, with or without food. Teneligliptin is well tolerated, with a safety profile characterized by a low incidence of adverse effects; however, patients should be monitored for hypersensitivity reactions and pancreatitis. Caution is advised in patients with renal or hepatic impairment, and dose adjustments may be necessary. Zita Tablet should be used under medical supervision, with regular monitoring of blood glucose levels to optimize therapeutic outcomes and minimize potential risks.